Spots Global Cancer Trial Database for classical hodgkin lymphoma
Every month we try and update this database with for classical hodgkin lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above | NCT05404945 | Classical Hodgk... | Pembrolizumab Doxorubicin Vinblastine Dacarbazine Brentuximab ved... | 60 Years - | University of Virginia | |
| A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma | NCT03209973 | Classical Hodgk... | Tislelizumab | 18 Years - | BeiGene | |
| Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma | NCT04510636 | Classical Hodgk... Relapsed Cancer Refractory Canc... | Pembrolizumab Bendamustine Hy... | 18 Years - | University Health Network, Toronto | |
| HD21 for Advanced Stages | NCT02661503 | Classical Hodgk... | Bleomycin Etoposide Doxorubicin Cyclophosphamid... Vincristine Procarbazine Prednisone Brentuximab Ved... Dacarbazine Dexamethasone | 18 Years - 60 Years | University of Cologne | |
| Phase Ib of L-NMMA and Pembrolizumab | NCT03236935 | Non-Small Cell ... Malignant Melan... Head and Neck S... Classical Hodgk... Urothelial Carc... DNA Repair-Defi... | L-NMMA Pembrolizumab | 18 Years - | The Methodist Hospital Research Institute | |
| Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | NCT03190174 | Ewing Sarcoma PEComa Epithelioid Sar... Desmoid Tumor Chordoma Non Small Cell ... Urothelial Carc... Melanoma Renal Cell Carc... Squamous Cell C... Hepatocellular ... Classical Hodgk... Colorectal Canc... MTOR Activating... | Nab-Rapamycin Nivolumab | 12 Years - | Sarcoma Oncology Research Center, LLC | |
| A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma | NCT05900765 | Classical Hodgk... | Zimberelimab 24... | 18 Years - | Sun Yat-sen University | |
| Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | NCT02940301 | Classical Hodgk... | Ibrutinib Laboratory Biom... Nivolumab | 19 Years - | Ohio State University Comprehensive Cancer Center | |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | NCT03212404 | Lung Neoplasms Carcinoma, Non-... Carcinoma, Smal... Malignant Mesot... Head and Neck C... Melanoma Merkel Cell Car... Renal Cell Carc... Urothelial Carc... Classical Hodgk... Cutaneous Squam... Non Hodgkin Lym... Endometrial Can... | CK-301 (cosibel... | 18 Years - | Checkpoint Therapeutics, Inc. | |
| Itacitinib + Everolimus in Hodgkin Lymphoma | NCT03697408 | Classical Hodgk... | Itacitinib Everolimus | 18 Years - | University of Pennsylvania | |
| Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma | NCT04838652 | Classical Hodgk... | Pembrolizumab p... | 18 Years - 65 Years | University of Cologne | |
| Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma | NCT04486391 | Classical Hodgk... | Tislelizumab Salvage Chemoth... | 18 Years - | BeiGene | |
| A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma | NCT06018129 | Classical Hodgk... Non-Hodgkin Lym... | GEN3017 | 16 Years - | Genmab | |
| Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents | NCT02684708 | Classical Hodgk... | cyclophosphamid... cyclo, vcr, pre... | - 25 Years | University of Giessen | |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | NCT03212404 | Lung Neoplasms Carcinoma, Non-... Carcinoma, Smal... Malignant Mesot... Head and Neck C... Melanoma Merkel Cell Car... Renal Cell Carc... Urothelial Carc... Classical Hodgk... Cutaneous Squam... Non Hodgkin Lym... Endometrial Can... | CK-301 (cosibel... | 18 Years - | Checkpoint Therapeutics, Inc. | |
| Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma | NCT04837859 | Classical Hodgk... | Tislelizumab | 18 Years - | University of Cologne | |
| A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | NCT04254107 | Non-small Cell ... Gastric Carcino... Gastroesophagea... Classical Hodgk... Diffuse Large B... Peripheral T-ce... Cutaneous Melan... Head and Neck S... Bladder Cancer Ovarian Cancer Triple Negative... Cervical Cancer | SEA-TGT sasanlimab brentuximab ved... | 18 Years - | Seagen Inc. | |
| Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | NCT02824029 | Classical Hodgk... Recurrent Hodgk... Refractory Hodg... | Ibrutinib Laboratory Biom... Pharmacological... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis | NCT03552003 | Classical Hodgk... | Treatment for c... | 65 Years - | Fondazione Italiana Linfomi - ETS | |
| Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy | NCT03480334 | Classical Hodgk... | Nivolumab plus ... | 18 Years - | University of Cologne | |
| HD21 for Advanced Stages | NCT02661503 | Classical Hodgk... | Bleomycin Etoposide Doxorubicin Cyclophosphamid... Vincristine Procarbazine Prednisone Brentuximab Ved... Dacarbazine Dexamethasone | 18 Years - 60 Years | University of Cologne | |
| Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis | NCT03552003 | Classical Hodgk... | Treatment for c... | 65 Years - | Fondazione Italiana Linfomi - ETS | |
| Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma | NCT04318080 | Classical Hodgk... | Tislelizumab | 18 Years - | BeiGene | |
| A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | NCT05362773 | Leukemia, Acute... Myelodysplastic... Classical Hodgk... Leukemia, B-cel... Leukemia, Hairy... Mastocytosis, A... Blastic Plasmac... Chronic Myeloid... | MGD024 | 18 Years - | MacroGenics | |
| Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin Lymphoma | NCT02815137 | Classical Hodgk... | Digital Polymer... | 18 Years - | Centre Henri Becquerel | |
| PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma | NCT03226249 | Classical Hodgk... Lymphocyte-Depl... Lymphocyte-Rich... Mixed Cellulari... Nodular Scleros... | Computed Tomogr... Dacarbazine Doxorubicin Hyd... Fludeoxyglucose... Laboratory Biom... Pembrolizumab Positron Emissi... Vinblastine Sul... | 18 Years - | Northwestern University | |
| A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma | NCT06018129 | Classical Hodgk... Non-Hodgkin Lym... | GEN3017 | 16 Years - | Genmab | |
| Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL | NCT03471351 | Classical Hodgk... | Tenalisib Pembrolizumab | 18 Years - | Rhizen Pharmaceuticals SA | |
| B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes | NCT03327571 | Classical Hodgk... Relapsed or Ref... | 18 Years - | Takeda | ||
| PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL | NCT04624984 | Classical Hodgk... Refractory or R... | PD-1 inhibitor PD-1 inhibitor,... | 18 Years - 75 Years | Sun Yat-sen University | |
| Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11) | NCT05008224 | Classical Hodgk... | Pembrolizumab Doxorubicin Vinblastine Dacarbazine Bleomycin Etoposide Cyclophosphamid... Vincristine Procarbazine Prednisone | 18 Years - | Merck Sharp & Dohme LLC | |
| Liquid Biopsy in Mature B-cell Tumors | NCT03280394 | Mature B-Cell N... | Liquid Biopsy | 18 Years - | Oncology Institute of Southern Switzerland | |
| Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma | NCT02243436 | CLASSICAL HODGK... | Brentuximab Ved... Etoposide Soludomerin Cisplatin Ara C | 18 Years - | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | |
| Immune Responses to COVID-19 Vaccination in Lymphoma Patients | NCT04858568 | Classical Hodgk... Diffuse Large B... Primary Mediast... High-grade B-ce... Burkitt Lymphom... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Chronic Lymphoc... Small Lymphocyt... Lymphoplasmacyt... Nodular Lymphoc... Peripheral T-ce... | 18 Years - | University Hospital Southampton NHS Foundation Trust | ||
| Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy | NCT03480334 | Classical Hodgk... | Nivolumab plus ... | 18 Years - | University of Cologne | |
| Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma | NCT04318080 | Classical Hodgk... | Tislelizumab | 18 Years - | BeiGene | |
| Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma | NCT03331341 | Classical Hodgk... | Dacarbazine Doxorubicin Hyd... Laboratory Biom... Pembrolizumab Vinblastine | 18 Years - | University of Washington | |
| Social Inequalities in the Participation and Activity in Children and Adolescents With Hodgkin-lymphoma | NCT02808520 | Classical Hodgk... | 10 Years - 18 Years | Martin-Luther-Universität Halle-Wittenberg | ||
| Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents | NCT02684708 | Classical Hodgk... | cyclophosphamid... cyclo, vcr, pre... | - 25 Years | University of Giessen | |
| Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma | NCT04837859 | Classical Hodgk... | Tislelizumab | 18 Years - | University of Cologne | |
| Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma | NCT04342936 | Classical Hodgk... | Camrelizumab Investigator's ... | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| LITT and Pembrolizumab in Recurrent Brain Metastasis | NCT04187872 | Melanoma Non-small Cell ... Renal Cell Carc... Small-cell Lung... Head and Neck S... Classical Hodgk... Primary Mediast... Urothelial Carc... Microsatellite ... Gastric Cancer Esophageal Canc... Cervical Cancer Hepatocellular ... Merkel Cell Car... Brain Metastase... | LITT + Pembroli... | 18 Years - 100 Years | University of Florida | |
| Prospective Comparison Between FDG-PET/MR and FDG-PET/CT in Classical Hodgkin Lymphoma and DLBC Non-Hodgkin Lymphoma | NCT03042247 | Diffuse Large B... Classical Hodgk... | FDG PET/TC and ... | 18 Years - 90 Years | Federico II University | |
| Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma | NCT04318080 | Classical Hodgk... | Tislelizumab | 18 Years - | BeiGene | |
| Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL | NCT03471351 | Classical Hodgk... | Tenalisib Pembrolizumab | 18 Years - | Rhizen Pharmaceuticals SA | |
| An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma | NCT03580564 | Classical Hodgk... | KL-A167 | 18 Years - | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | |
| Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma | NCT04510636 | Classical Hodgk... Relapsed Cancer Refractory Canc... | Pembrolizumab Bendamustine Hy... | 18 Years - | University Health Network, Toronto | |
| Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma | NCT02243436 | CLASSICAL HODGK... | Brentuximab Ved... Etoposide Soludomerin Cisplatin Ara C | 18 Years - | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | |
| Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy | NCT05352828 | Classical Hodgk... Hodgkin Disease... Hodgkin Disease... | Nivolumab Autologous CD30... Fludarabine Bendamustine | 12 Years - | Tessa Therapeutics | |
| Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma | NCT03652441 | Classical Hodgk... | Brentuximab Ved... | 18 Years - | University of Cologne | |
| Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas | NCT03205891 | Malignant Neopl... Classical Hodgk... Anaplastic Larg... CD30+ Periphera... | Brentuximab Ved... TAK228 Glucose Monitor | 18 Years - | M.D. Anderson Cancer Center | |
| Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy | NCT05352828 | Classical Hodgk... Hodgkin Disease... Hodgkin Disease... | Nivolumab Autologous CD30... Fludarabine Bendamustine | 12 Years - | Tessa Therapeutics | |
| Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | NCT02824029 | Classical Hodgk... Recurrent Hodgk... Refractory Hodg... | Ibrutinib Laboratory Biom... Pharmacological... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes | NCT03327571 | Classical Hodgk... Relapsed or Ref... | 18 Years - | Takeda | ||
| Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment. | NCT01022996 | Hodgkin Lymphom... | Everolimus (RAD... | 18 Years - | Novartis | |
| Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy | NCT03480334 | Classical Hodgk... | Nivolumab plus ... | 18 Years - | University of Cologne | |
| Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma | NCT04342936 | Classical Hodgk... | Camrelizumab Investigator's ... | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma | NCT00742027 | Classical Hodgk... | Panobinostat | 18 Years - | Novartis | |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | NCT03212404 | Lung Neoplasms Carcinoma, Non-... Carcinoma, Smal... Malignant Mesot... Head and Neck C... Melanoma Merkel Cell Car... Renal Cell Carc... Urothelial Carc... Classical Hodgk... Cutaneous Squam... Non Hodgkin Lym... Endometrial Can... | CK-301 (cosibel... | 18 Years - | Checkpoint Therapeutics, Inc. | |
| Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | NCT02940301 | Classical Hodgk... | Ibrutinib Laboratory Biom... Nivolumab | 19 Years - | Ohio State University Comprehensive Cancer Center | |
| Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | NCT02824029 | Classical Hodgk... Recurrent Hodgk... Refractory Hodg... | Ibrutinib Laboratory Biom... Pharmacological... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy | NCT03527628 | Classical Hodgk... Hodgkin Lymphom... Hodgkin Disease Hodgkin Lymphom... | Adriamycin Cyclophosphamid... Vinblastine Dacarbazine Brentuximab Ved... ABVD | 14 Years - 60 Years | King Abdullah International Medical Research Center | |
| Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment. | NCT01022996 | Hodgkin Lymphom... | Everolimus (RAD... | 18 Years - | Novartis | |
| NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | NCT05714553 | Advanced Cancer Advanced Solid ... Neoplasm Malign... Metastatic Canc... Melanoma Classical Hodgk... Non Small Cell ... Renal Cell Carc... Urothelial Carc... Head and Neck S... Subungual Squam... Oesophageal Car... MSI-H Colorecta... Gastric Cancer Triple Negative... Endometrial Car... Pleural Mesothe... | Fosifloxuridine... Leucovorin Pembrolizumab Docetaxel | 18 Years - | NuCana plc | |
| Phase Ib of L-NMMA and Pembrolizumab | NCT03236935 | Non-Small Cell ... Malignant Melan... Head and Neck S... Classical Hodgk... Urothelial Carc... DNA Repair-Defi... | L-NMMA Pembrolizumab | 18 Years - | The Methodist Hospital Research Institute | |
| A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | NCT05362773 | Leukemia, Acute... Myelodysplastic... Classical Hodgk... Leukemia, B-cel... Leukemia, Hairy... Mastocytosis, A... Blastic Plasmac... Chronic Myeloid... | MGD024 | 18 Years - | MacroGenics | |
| PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma | NCT03226249 | Classical Hodgk... Lymphocyte-Depl... Lymphocyte-Rich... Mixed Cellulari... Nodular Scleros... | Computed Tomogr... Dacarbazine Doxorubicin Hyd... Fludeoxyglucose... Laboratory Biom... Pembrolizumab Positron Emissi... Vinblastine Sul... | 18 Years - | Northwestern University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
